Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons — 29 U.S. Jurisdictions, May 22–September 3, 2022
Authors: Jennifer L. Farrar, Nathaniel M. Lewis, Kennedy Houck, Michelle Canning, Amy Fothergill, Amanda B. Payne, Adam L. Cohen, Joshua Vance, Bridget Brassil, Erin Youngkin, Bailey Glenn, Anil Mangla, Nikki Kupferman, Katharine Saunders, Cristina Meza, Dawn Nims, Susan Soliva, Brandon Blouse, Tiffany Henderson, Emily Banerjee, Brooklyn White, Rachael Birn, Anna M. Stadelman, Meaghan Abrego, Meagan McLafferty, Michael G. Eberhart, Michael Pietrowski, Sandra Miranda De León, Emma Creegan, Abdoulaye Diedhiou, Caleb Wiedeman, Jade Murray-Thompson, Elizabeth McCarty, Jessica Marcinkevage, Anna Kocharian, Elizabeth A. Torrone, Logan C. Ray, Daniel C. Payne, Matthew Cole, Lauren Roper, Hazel Shah, Louise McNitt, Stephanie Gretsch, Melissa Pike, Patricia Firmender, Will Still, Jamie Ahlers, Aman Punwani, Komal Patel, Nam-Kyu Cho, Marcia Pearlowitz, Petra Schubert, Ryan Malosh, Sydney Kuramoto, Matthew Donahue, Miranda Durham, Charlotte DelBarba, Kelly Cogswell, Julie Miedlar, Dana Perella, Julian D. Cordero Calderon, Taidy Perez, Jacqueline Logan, Abigail Collingwood, Naihlah Smith, Rachel Klos
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

Vaccinated Persons TeamAs of November 14, 2022, monkeypox (mpox) cases had been reported from more than 110 countries, including 29,133 cases in the United States.*Among U.S. cases to date, 95% have occurred among males (1).After the first confirmed U.S. mpox case on May 17, 2022, limited supplies of JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic) were made available to jurisdictions for persons exposed to mpox.JYNNEOS vaccine was approved by the Food and Drug Administration (FDA) in 2019 as a 2-dose series (0.5 mL per dose, administered subcutaneously) to prevent smallpox and mpox disease.† On August 9, 2022, FDA issued an emergency use authorization to allow administration of JYNNEOS vaccine by intradermal injection (0.1 mL per dose) (2).A previous report on U.S. mpox cases during July 31-September 3, 2022, suggested that 1 dose of vaccine offers some protection against mpox (3).This report describes demographic and clinical characteristics of cases occurring ≥14 days after receipt of 1 dose of JYNNEOS vaccine and compares them with characteristics of cases among unvaccinated persons with mpox and with the vaccine-eligible vaccinated population in participating jurisdictions.During May 22-September 3, 2022, among 14,504 mpox cases reported from 29 participating U.S. jurisdictions, § 6,605 (45.5%) had available vaccination information and were included in the analysis.Among included cases, 276 (4.2%) were among persons who had received 1 dose of vaccine ≥14 days before illness onset.Mpox cases that occurred in these vaccinated persons were associated with lower percentage of hospitalization (2.1% versus 7.5%), fever, headache, malaise, myalgia, and chills, compared with cases in unvaccinated persons.Although 1 dose of JYNNEOS vaccine offers some protection from disease, mpox infection can occur after receipt of 1 dose, and the duration of * https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html